Patents Assigned to AstraZeneca
  • NOVEL FUSED HETEROCYCLES AND USES THEREOF
    Publication number: 20080153854
    Abstract: This invention relates to novel compounds having the formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as defined in the specification and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment or prophylaxis of cancer.
    Type: Application
    Filed: February 15, 2008
    Publication date: June 26, 2008
    Applicant: AstraZeneca AB
    Inventors: Brian Aquila, Michael Howard Block, Audrey Davies, Jayachandran Ezhuthachan, Sandra Filla, Richard William Luke, Timothy Pontz, Daniel John Russell, Maria-Elena Theoclitou, XiaoLan Zheng
  • Novel Quinoline-Carbaxamides as Jak3 Kinase Modulators
    Publication number: 20080153799
    Abstract: The present invention relates to novel compounds which are JAK3 Kinase inhibitors, methods for their preparation and pharmaceutical compositions comprising them.
    Type: Application
    Filed: February 7, 2005
    Publication date: June 26, 2008
    Applicant: ASTRAZENECA AB
    Inventors: David Laurent, Jorgen Gustafsson, Karolina Lawitz, Tesfaledet Mussie, Antonios Nikitidis
  • TARGETED BINDING AGENTS DIRECTED TO uPAR AND USES THEREOF
    Publication number: 20080152587
    Abstract: Targeted binding agents directed to the antigen uPAR and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the antigen uPAR. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies.
    Type: Application
    Filed: April 9, 2007
    Publication date: June 26, 2008
    Applicants: Amgen Fremont Inc., AstraZeneca AB
    Inventors: Qing Zhou, Stephen Charles Emery, Paul Elvin
  • Compounds Having Tie2 (Tek) Activity
    Publication number: 20080153838
    Abstract: The invention relates to a compound of the Formula I. or salt, prodrug or solvate thereof, wherein R1, R5, R6, D, A, B, L, n, m and p are as defined in the description. The invention also relates to pharmaceutical compositions of said compounds, the use of said compounds as medicaments and in the production of an anti-angiogenic effect in a warm-blooded animal. The invention also relates to processes for the preparation of said compounds.
    Type: Application
    Filed: February 2, 2006
    Publication date: June 26, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Clifford David Jones, Richard Williams Arthur Luke, William McCoull
  • NOVEL CRYSTALLINE COMPOUND
    Publication number: 20080153800
    Abstract: A novel crystalline form of 3-{[5-(azetidin-1-ylcarbonyl)pyrazin-2-yl]oxy}-5-[(1-methylethyl)oxy]-N-1H-pyrazol-3-ylbenzamide is described in the specification. This compound is a glucokinase (GLK or GK) activator and useful as a pharmaceutical agent in the treatment or prevention of a disease or medical condition mediated through GLK, leading to a decreased glucose threshold for insulin secretion. Processes for the manufacture of the crystalline form, pharmaceutical compositions comprising the crystalline form and the use of the crystalline form in medical treatment are also described.
    Type: Application
    Filed: December 21, 2007
    Publication date: June 26, 2008
    Applicant: AstraZeneca AB
    Inventors: James MCCABE, Gary Peter Tomkinson
  • Compounds effecting glucokinase
    Patent number: 7390908
    Abstract: The invention relates to the use of a compound of Formula (I) or a salt, solvate or prodrug thereof, wherein R1, R2, R3, n and m are as described in the specification, in the preparation of a medicament for the treatment or prevention of a disease condition mediated through glucokinase (GLK), such as type 2 diabetes. The invention also relates to a novel group of compounds of Formula (I) and to methods for preparing compounds of Formula (I).
    Type: Grant
    Filed: August 15, 2002
    Date of Patent: June 24, 2008
    Assignee: AstraZeneca AB
    Inventors: Scott Boyd, Peter William Rodney Caulkett, Rodney Brian Hargreaves, Suzanne Saxon Bowker, Roger James, Craig Johnstone, Clifford David Jones, Darren McKerrecher, Michael Howard Block
  • Pyrimidine Compounds Having Tie-2 (Tek) Inhibitory Activity
    Publication number: 20080146599
    Abstract: The invention relates to a compound of the Formula (I) or salt, prodrug or solvate thereof, wherein Rx, Ry, Rz, R5, R6, A, B, L, n and m are as defined in the description. The invention also relates to pharmaceutical compositions of said compounds, the use of said compounds as medicaments and in the production of an anti-angiogenic effect in a warm blooded animal. The invention also relates to processes for the preparation of said compounds.
    Type: Application
    Filed: January 27, 2006
    Publication date: June 19, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Clifford David Jones, Richard William Arthur Luke, William McCoull
  • Chemical Compounds
    Publication number: 20080146570
    Abstract: The invention relates to chemical compounds, or pharmaceutically acceptable salts thereof, of the formula (I): which possess B-Raf inhibitory activity and are accordingly useful for their anti-cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm-blooded animal such as man.
    Type: Application
    Filed: January 24, 2006
    Publication date: June 19, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Brian Aquila, Paul Lyne, Timothy Pontz
  • Novel Oxabispidine Compounds And Their Use In The Treatment Of Cardiac Arrhythmias
    Publication number: 20080146812
    Abstract: There is provided compounds of formula I, wherein R1, R2, R4, R41 to R46, A, B and G have meanings given in the description, which are useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial and ventricular arrhythmias.
    Type: Application
    Filed: February 12, 2008
    Publication date: June 19, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Annika Bjore, Ulrik Gran, Gert Strandlund
  • Novel Biaromatic Compounds, Inhibitors of the P2X7-Receptor
    Publication number: 20080146612
    Abstract: The invention provides compounds of formula (I), or a pharmaceutically acceptable salt thereof, wherein Ar1 represents a group (II), (III), (IV) or (V), and A, Ar2, n, R1, R2, R3, R4 and R5 are as defined in the specification; a process for their preparation; pharmaceutical compositions containing them; and their use in therapy.
    Type: Application
    Filed: January 25, 2006
    Publication date: June 19, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Toby Thompson, Paul Willis
  • Isothermal Titration Calorimetry Assays
    Publication number: 20080145840
    Abstract: A method for identifying a modulator of a biological process or a biomolecule.
    Type: Application
    Filed: June 30, 2004
    Publication date: June 19, 2008
    Applicant: AstraZeneca AB
    Inventors: Ann Eakin, Stewart Fisher, Irene Karantzeni, Gunther Kern
  • Method for Determining Responsiveness to Chk1 Inhibitors
    Publication number: 20080145358
    Abstract: The invention is directed at a method for predicting a patient's responsiveness to a CHK1 inhibitor The method includes providing a sample from a test patient who is being treated with a DNA damaging agent; and determining for the presence of an activated CHK1 signal transduction pathway molecule, wherein the presence of an activated CHK1 signal transduction pathway molecule is indicative that a CHK1 inhibitor should be administered to the patient.
    Type: Application
    Filed: February 16, 2006
    Publication date: June 19, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Sonya Zabludoff, Louise Bergeron
  • Benzimidazol derivatives modulate chemokine receptors
    Patent number: 7388020
    Abstract: The invention provides compounds of general formula (I) wherein A, X, m, R1, N, R2, Z1, Z2, Q, R3, R4, R5, R6, R7, R8, t and R16 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy
    Type: Grant
    Filed: March 18, 2002
    Date of Patent: June 17, 2008
    Assignee: AstraZeneca AB
    Inventors: Tomas Eriksson, Svetlana Ivanova, Hans Lönn
  • Non-Anilinic Derivatives Of Isothiazol-3(2H)-Thione 1,1-Dioxides As Liver X Receptor Modulators
    Publication number: 20080139616
    Abstract: The present invention relates to certain novel compounds of the formula (I) to processes for preparing such compounds, to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) ? (NR1H3) and/or ? (NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer's disease, lipid disorders (dyslipidemias) whether or not associated with insulin resistance, type 2 diabetes and other manifestations of the metabolic syndrome, to methods for their therapeutic use and to pharmaceutical compositions containing them.
    Type: Application
    Filed: January 9, 2006
    Publication date: June 12, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Lanna Li, Marianne Swanson, Kay Brickmann
  • New Compounds
    Publication number: 20080139607
    Abstract: The present invention relates to new compounds of formula (I), (II), or (III) wherein R1, R2, R3, R4, R5 and W are as defined herein, and methods of using the compounds to inhibit PAI-1 and to treat PAI-1 related disorders.
    Type: Application
    Filed: October 31, 2007
    Publication date: June 12, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Fredrik Almqvist, Erik Chorell, Pralay Das, Hans Emtenas, Ola Fjellstrom, Mickael Mogemark, Magnus Polla, Veronica Aberg
  • Nicotinic Acetylcholine Receptor Ligands 101
    Publication number: 20080139600
    Abstract: Nicotinic acetylcholine receptor ligands of Formula I wherein X, n, R1 and R2 are as described in the specification, diastereoisomers, enantiomers, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing, and methods for using the same.
    Type: Application
    Filed: May 17, 2007
    Publication date: June 12, 2008
    Applicant: AstraZeneca AB
    Inventors: Hui-Fang Chang, Christopher Holmquist, Eifion Phillips, Timothy Piser, Thomas Simpson, Rebecca Urbanek, James Woods, Hui Xiong
  • Chemical Compound
    Publication number: 20080139613
    Abstract: The present invention relates to 4-{(1R,3R)-1-(3,5-difluorophenyl)-3-[4-(3-ethyl-5-isopropyl-4H-1,2,4-triazol-4-yl)piperidin-1-yl]butyl}-1-(methylsulfonyl)piperidine (I): or a pharmaceutically acceptable salt thereof, as well as to processes for preparing such a compound, to pharmaceutical compositions comprising such a compound and to the use of such a compound in the treatment of CCR5 mediated disease states.
    Type: Application
    Filed: December 10, 2007
    Publication date: June 12, 2008
    Applicant: AstraZeneca AB
    Inventors: Dearg Sutherland Brown, Alan Wellington Faull, Steven Swallow
  • Chemical Compound
    Publication number: 20080139612
    Abstract: The present invention relates to 4-[3-(1,1-difluoroethyl)-5-methyl-4H-1,2,4-triazol-4-yl]-1-{(1R,3R)-3-(3,5-difluorophenyl)-1-methyl-3-[1-(methylsulfonyl)piperidin-4-yl]propyl}piperidine (I): or a pharmaceutically acceptable salt thereof, as well as processes for the preparation of this compound and its use in the treatment of CCR5 disease states.
    Type: Application
    Filed: December 10, 2007
    Publication date: June 12, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Alan Wellington Faull, Steven Swallow
  • New Process 298
    Publication number: 20080139846
    Abstract: A process for preparing a compound of formula I wherein R1 is H, C1-6alkyl, C2-6alkenyl, C1-6alkoxy, —OH, or amino; and n, m, and p are independently selected from 0, 1 and 2; which process comprises reacting a compound of formula II, by combining it with a reducing agent in a suitable solvent into a reaction mixture.
    Type: Application
    Filed: August 28, 2007
    Publication date: June 12, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Lars Hansson, Martin Hedberg
  • Pyrazolylaminopyridine Derivatives Useful as Kinases Inhibitors
    Publication number: 20080139561
    Abstract: This invention relates to novel compounds having the Formula (I) to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment for cancer.
    Type: Application
    Filed: February 1, 2006
    Publication date: June 12, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Audrey Davies, Michelle Lamb, Paul Lyne, Tao Wang, Dingwei Yu, Peter Mohr, Bin Wang